Global Information
회사소개 | 문의 | 비교리스트

거대세포바이러스(CMV) 및 단순포진바이러스(HSV) 검사 : 체외진단 시장 분석과 예측 모델

Cytomegalovirus (CMV) Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model

리서치사 GlobalData
발행일 2018년 12월 상품 코드 640284
페이지 정보 영문
가격
US $ 7,500 ₩ 9,045,000 Excel by E-mail (Single User License)
US $ 15,000 ₩ 18,090,000 Excel by E-mail (Site License)
US $ 22,500 ₩ 27,135,000 Excel by E-mail (Global License)


거대세포바이러스(CMV) 및 단순포진바이러스(HSV) 검사 : 체외진단 시장 분석과 예측 모델 Cytomegalovirus (CMV) Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model
발행일 : 2018년 12월 페이지 정보 : 영문

세계 주요 39개국의 거대세포바이러스(CMV) 및 단순포진바이러스(HSV) 검사 시장을 조사했으며, 시장 및 제품 개요, 주요 산업 동향, 검사 건수·설치 대수·신규 판매량·평균 판매 가격 등의 각종 데이터와 추이, 검사 구분별 연간 매출 추이와 예측, 경쟁 환경과 기업 점유율, 애널리스트의 각종 분석 등을 정리하여 전해드립니다.

1. 주요 조사 내용

  • 현재 시판되고 있는 제품과 경쟁 동향
  • 주요 산업 동향 리뷰
  • 연간 매출 추이와 예측 : 각종 구분별
    • 거대세포바이러스(CMV) 검사
    • 단순포진바이러스(HSV) 검사
  • 각종 상세 데이터
    • 총 검사건수
    • 설치 대수
    • 신규 판매량
    • 평균 판매 가격 등
  • 기업 점유율
  • 애널리스트의 분석

2. 본 보고서의 이점

  • 파이프라인 제품과 기술을 리뷰하고, 견고한 파이프라인을 갖춘 기업을 특정할 수 있기 때문에 인라이선싱&아웃라이선싱 전략 구축과 설계가 가능
  • 제품 시장을 형성·추진하는 동향을 이해함으로써 사업 전략 구축이 가능
  • 주요 동향, 혁신적 제품과 기술, 영향력을 가진 기업 등에 대한 이해를 심화하여 매출 창출이 가능
  • 경쟁 환경을 이해하고, 시장 리더의 점유율을 분석함으로써 효과적인 판매/마케팅 전략 구축이 가능
  • 경쟁 우위를 확보하기 위해서 잠재력 있는 제품 포트폴리오를 보유한 신흥기업을 파악하고, 효과적인 대응 전략 수립이 가능
  • 세계/국가별 기기 매출 추이와 예측 추적이 가능
  • 통합/투자/전략적 제휴를 위한 최대 기회를 제공하는 시장 부문과 카테고리를 파악하여 판매·마케팅 활동 체계화가 가능
LSH 18.06.01

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

Cytomegalovirus (CMV) Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area.

Cytomegalovirus (CMV) represents the most common congenital, viral infection in the developed world and awareness of this disease is increasing. Few countries have official guidelines in place for CMV screening but in general testing tends to be performed for sperm donations, immunocompromised cases, and pregnant women. Diagnosis of CMV infections is complex as symptoms are often non-specific and mimic mononucleosis or the flu. Approximately 21-25% of primary CMV infections are symptomatic in pregnant women. Conversely, sources indicate that women with repeat or secondary CMV infections typically do not show symptoms.

The majority of CMV tests are performed using Enzyme Immuno Assay (EIA) devices, which detect the presence of both IgG and IgM antibodies in patient blood. These assays are highly sensitive and provide high-throughput capabilities. Molecular assays and nucleic acid amplification test (NAAT) devices are also sometimes employed for diagnosis of CMV infection, confirmatory testing, or performed for CMV viral load testing in immunocompromised or transplant patients.

Each of the covered 39 country's color-coded and fully-sourced market models are equipped with epidemiology based indications with procedure volumes. To increase the data transparency, the interactive excel deliverable covers installed base, new sales volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available). Moreover, analyst comments with qualitative insight offer context for quantitative data.

Key Inclusions of the market model

Currently marketed Cytomegalovirus (CMV) Tests and evolving competitive landscape -

  • Insightful review of the key industry trends.
  • Annualized total Cytomegalovirus (CMV) Tests market revenue by segment and market outlooks from 2015-2028.
  • Granular data on total procedures, units, average selling prices and market values by segment.

Global, Regional and Country level market specific insights -

  • Qualitative market specific information is available with global trends further broken down into regional trends. In addition GlobalData analysts provide unique country specific insights on the market.
  • SWOT analysis for this Cytomegalovirus (CMV) Tests market.
  • Competitive dynamics insights and trends provided for this Cytomegalovirus (CMV) Tests market.

Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.

  • Country specific overview of the healthcare system.
  • Country specific reimbursement policies.
  • Country specific medtech regulatory landscape.

Robust methodologies and sources enable the model to provide extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.

Companies covered: Abbott Laboratories, American Master Tech Scientific Inc, Beckman Coulter Inc, bioMerieux Inc, Bion Enterprises Ltd, Bio-Rad Laboratories, Inc, DiaSorin Inc, Erba Diagnostics Inc, Immucor, Inc., Luminex Corp, Merck KGaA, Qiagen NV, Quidel Corporation, Altona Diagnostics GmbH, Roche Diagnostics International Ltd, Siemens Healthineers, Trinity Biotech Plc, Others

Countries covered: United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina and Chile.

Scope

This Market Model gives important, expert insight you won't find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for -

  • CMO executives who must have deep understanding of the Cytomegalovirus (CMV) Tests marketplace to make strategic planning and investment decisions.
  • Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management.
  • Private equity investors that need a deeper understanding of the market to identify and value potential investment targets.

Reasons to buy

The model will enable you to -

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving Prenatal Screening market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the Prenatal Screening market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the company share of market leaders.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track device sales in the global and country-specific Prenatal Screening market from 2015-2028.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Back to Top
전화 문의
F A Q